Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association

Transthyretin amyloid cardiomyopathy (ATTR-CM) results in a restrictive cardiomyopathy caused by extracellular deposition of transthyretin, normally involved in the transportation of the hormone thyroxine and retinol-binding protein, in the myocardium. Enthusiasm about ATTR-CM has grown as a result...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Circulation (New York, N.Y.) Ročník 142; číslo 1; s. e7
Hlavní autoři: Kittleson, Michelle M, Maurer, Mathew S, Ambardekar, Amrut V, Bullock-Palmer, Renee P, Chang, Patricia P, Eisen, Howard J, Nair, Ajith P, Nativi-Nicolau, Jose, Ruberg, Frederick L
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States 07.07.2020
Témata:
Algorithms
Alleles
Amyloidosis - diagnosis
Amyloidosis - etiology
Amyloidosis - metabolism
Amyloidosis - therapy
Animals
Biomarkers
Cardiomyopathies - diagnosis
Cardiomyopathies - etiology
Cardiomyopathies - metabolism
Cardiomyopathies - therapy
Clinical Decision-Making
Disease Management
Disease Susceptibility
Gene Silencing
Genetic Predisposition to Disease
Genotype
Heart Function Tests
Humans
Magnetic Resonance Imaging
Molecular Diagnostic Techniques
Prealbumin - genetics
Prealbumin - metabolism
heart failure
amyloidosis
transthyretin
AHA Scientific Statements
ISSN:1524-4539, 1524-4539
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Transthyretin amyloid cardiomyopathy (ATTR-CM) results in a restrictive cardiomyopathy caused by extracellular deposition of transthyretin, normally involved in the transportation of the hormone thyroxine and retinol-binding protein, in the myocardium. Enthusiasm about ATTR-CM has grown as a result of 3 simultaneous areas of advancement: Imaging techniques allow accurate noninvasive diagnosis of ATTR-CM without the need for confirmatory endomyocardial biopsies; observational studies indicate that the diagnosis of ATTR-CM may be underrecognized in a significant proportion of patients with heart failure; and on the basis of elucidation of the mechanisms of amyloid formation, therapies are now approved for treatment of ATTR-CM. Because therapy for ATTR-CM may be most effective when administered before significant cardiac dysfunction, early identification of affected individuals with readily available noninvasive tests is essential. This scientific statement is intended to guide clinical practice and to facilitate management conformity by covering current diagnostic and treatment strategies, as well as unmet needs and areas of active investigation in ATTR-CM.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1524-4539
1524-4539
DOI:10.1161/CIR.0000000000000792